In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …

The 2016 revised fourth edition of the World Health Organization (WHO) classification of
central nervous system (CNS) tumors incorporated molecular features with histologic …

To follow the revision of the fourth edition of WHO classification and the recent progress on
the management of diffuse gliomas, the joint guideline committee of Chinese Glioma …

Primary CNS tumours refer to a heterogeneous group of tumours arising from cells within the
CNS, and can be benign or malignant. Malignant primary brain tumours remain among the …

The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of
rarer CNS tumour types exists. The classification of these tumours is increasingly based on …

Summary The European Association for Neuro-Oncology guideline provides
recommendations for the clinical care of adult patients with astrocytic and oligodendroglial …

Abstract The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate
dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation …

The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of
adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas …

Purpose To provide guidance to clinicians regarding therapy for diffuse astrocytic and
oligodendroglial tumors in adults. Methods ASCO and the Society for Neuro-Oncology …

Background Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting
molecular heterogeneity of the disease. We compared two different, single-modality …